| PubChem CID | Drug (INN) | Original Targets (Gene Symbol) | Original Indications |
|---|---|---|---|
| 5566 | trifluoperazine | ADCY1, ADCY3, ADCY4, ADCY6, ADCY8, ADCY9, ADRA1A, ANXA10, ANXA13, ANXA2, ANXA3, ANXA5, ANXA6, CALM1, CALY, DRD2, DRD4, DRD5, F2, FDPS, GRK7, LTB4R, MYH1, MYH2, MYH4, MYH7B, MYL1, MYL12A, MYL2, MYL7, MYL9, MYLK, MYO15A, MYO18B, MYO1C, MYO1D, MYO1E, MYO3A, MYO3B, MYO5B, MYO5C, NDUFAF3, NDUFS5, S100A4, SLC1A5, SLC5A11, SLC7A5, TNNC1, TNNI3, TNNT2 | Antipsychotic Agents, Antiemetics, Alcoholic Intoxication, Chronic, Bipolar Disorder, Catatonia, Hallucinations, Psychotic Disorders, Schizophrenia, Paranoid Schizophrenia, Brain Injuries, Mental deficiency, Alcoholism, Alcohol abuse, Bipolar disorder, Bipolar I disorder, Hallucination, Psychotic disorder, Schizophrenia, paranoid type, Brain injury |
| Drug Name (INN) |
Predicted Drug Target (Uniprot AC) |
Target Prediction Score (Range: 0~1) |
Binding or Not (Positive binding: 1) |
Novel Positives (Novel candidate: 1) |
|---|---|---|---|---|
| trifluoperazine | EPHA5 (P54756) | 0.1286 | 0 | - |
| trifluoperazine | O30124 | 0.1286 | 0 | - |
| trifluoperazine | TF (P02787) | 0.1285 | 0 | - |
| trifluoperazine | CACNA1I (Q9P0X4) | 0.128 | 0 | - |
| trifluoperazine | CATSPER4 (Q7RTX7) | 0.1274 | 0 | - |
| trifluoperazine | KCNH3 (Q9ULD8) | 0.127 | 0 | - |
| trifluoperazine | LIPE (Q05469) | 0.1267 | 0 | - |
| trifluoperazine | PRLR (P16471) | 0.1266 | 0 | - |
| trifluoperazine | P35563 | 0.1265 | 0 | - |
| trifluoperazine | P0A749 | 0.1263 | 0 | - |
| trifluoperazine | ABCC1 (P33527) | 0.1261 | 0 | - |
| trifluoperazine | SHH (Q15465) | 0.1257 | 0 | - |
| trifluoperazine | NCOA2 (Q15596) | 0.1256 | 0 | - |
| trifluoperazine | MGAM (O43451) | 0.1254 | 0 | - |
| trifluoperazine | CASP9 (P55211) | 0.1253 | 0 | - |
| trifluoperazine | GRM2 (Q14416) | 0.1251 | 0 | - |
| trifluoperazine | ASS1 (P00966) | 0.125 | 0 | - |
| trifluoperazine | Q63704 | 0.125 | 0 | - |
| trifluoperazine | KCNJ9 (Q92806) | 0.1249 | 0 | - |
| trifluoperazine | CYP27B1 (O15528) | 0.1248 | 0 | - |
| trifluoperazine | SMO (Q99835) | 0.1248 | 0 | - |
| trifluoperazine | L1CAM (P32004) | 0.1246 | 0 | - |
| trifluoperazine | NR3C2 (P08235) | 0.1245 | 0 | - |
| trifluoperazine | P03198 | 0.1241 | 0 | - |
| trifluoperazine | ATP6 (P00846) | 0.1241 | 0 | - |
| trifluoperazine | ST14 (Q9Y5Y6) | 0.124 | 0 | - |
| trifluoperazine | IMPDH1 (P20839) | 0.1239 | 0 | - |
| trifluoperazine | ITGAV (P06756) | 0.1239 | 0 | - |
| trifluoperazine | FLT4 (P35916) | 0.1238 | 0 | - |
| trifluoperazine | P06149 | 0.1237 | 0 | - |
| trifluoperazine | Q8K0H1 | 0.1237 | 0 | - |
| trifluoperazine | P08220 | 0.1234 | 0 | - |
| trifluoperazine | RYR2 (Q92736) | 0.1234 | 0 | - |
| trifluoperazine | AR (P10275) | 0.123 | 0 | - |
| trifluoperazine | RYR3 (Q15413) | 0.123 | 0 | - |
| trifluoperazine | O15648 | 0.1229 | 0 | - |
| trifluoperazine | P05193 | 0.1227 | 0 | - |
| trifluoperazine | A2M (P01023) | 0.1227 | 0 | - |
| trifluoperazine | SLC25A15 (Q9Y619) | 0.1227 | 0 | - |
| trifluoperazine | P23439 | 0.1226 | 0 | - |
| trifluoperazine | OXCT2 (Q9BYC2) | 0.1224 | 0 | - |
| trifluoperazine | NDUFV2 (P19404) | 0.1221 | 0 | - |
| trifluoperazine | P0AAI5 | 0.1221 | 0 | - |
| trifluoperazine | P11439 | 0.1221 | 0 | - |
| trifluoperazine | AURKA (O14965) | 0.1213 | 0 | - |
| trifluoperazine | ADRA1D (P25100) | 0.1212 | 0 | - |
| trifluoperazine | GABRB1 (P18505) | 0.1212 | 0 | - |
| trifluoperazine | AIFM1 (O95831) | 0.1212 | 0 | - |
| trifluoperazine | JAK1 (P23458) | 0.1211 | 0 | - |
| trifluoperazine | RRM1 (P23921) | 0.1211 | 0 | - |
| Drug (INN) |
Drug Mechanism (Gene ontology) |
Mechanism Score (Range: 0~1) |
Positive or not (Positive: 1) |
|---|---|---|---|
| trifluoperazine | GO:0006281 DNA repair | 1 | 1 |
| trifluoperazine | GO:0031570 DNA integrity checkpoint | 1 | 1 |
| trifluoperazine | GO:0007049 cell cycle | 0.875 | 1 |
| trifluoperazine | GO:0008283 cell population proliferation (viability) | 0.7 | 1 |
| trifluoperazine | GO:0071456 cellular response to hypoxia | 0.3333 | 0 |
| trifluoperazine | GO:0001525 angiogenesis | 0.2857 | 0 |
| trifluoperazine | GO:0008283 cell population proliferation | 0.25 | 0 |
| trifluoperazine | GO:0006954 inflammatory response | 0.2 | 0 |
| trifluoperazine | GO:0008219 cell death | 0.0625 | 0 |
| trifluoperazine | GO:0006096 glycolytic process | 0 | 0 |
| trifluoperazine | GO:0016477 cell migration | 0 | 0 |
| trifluoperazine | GO:0001837 epithelial to mesenchymal transition | 0 | 0 |
| trifluoperazine | GO:0002418 immune response to tumor cell | 0 | 0 |
| trifluoperazine | GO:0010833 telomere maintenance via telomere lengthening | 0 | 0 |
| trifluoperazine | GO:0001570 vasculogenesis | 0 | 0 |
| trifluoperazine | GO:0007155 cell adhesion | 0 | 0 |
| trifluoperazine | GO:0016049 cell growth | 0 | 0 |
| trifluoperazine | GO:0006915 apoptotic process | 0 | 0 |
| Drug (INN) |
Cancer Type | Indication Score (Range: 0~1) |
Cancer Drug or Not (Positive indication: 1) |
Novel Positives (Novel candidate: 1) |
|---|---|---|---|---|
| trifluoperazine | Cancer(general) | 0.6236 | 0 | - |